Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Aktis Oncology›
Website
AddedFeb 15, 2024
UpdatedJun 18, 2026
Aktis Oncology

Aktis Oncology

Series A

Aktis Oncology: Biotech pioneer in developing targeted radiopharmaceuticals for solid tumors.

HQ
Boston, MA, US
Founded
2021
Loading
Overview
Compare
Fundraising
Employees
News
Website

Aktis Oncology - Website

An index of every page on aktisoncology.com, by section.

19 pages across 8 sections · Updated Jul 16, 2026·

Homepage

Aktis Oncology's front door: current positioning and top-line messaging.

aktisoncology.com
  • Homepage

TeamTodd Foley

Leadership and the people behind Aktis Oncology, as the company presents them.

  • Todd Foley/team/todd-foley
  • Erik Chelius Phd/team/erik-chelius-phd
  • Johannes Czernin Md/team/johannes-czernin-md
  • Dane Wittrup Phd/team/dane-wittrup-phd
  • Carlos Rodriguez/team/carlos-rodriguez
  • Patrick Baeuerle Phd/team/patrick-baeuerle-phd

PrivacyPrivacy Policy

How Aktis Oncology collects, uses, and safeguards data: the canonical policy set.

aktisoncology.com/privacy-policy

Products / ServicesPlatform

The products and services as Aktis Oncology markets them.

aktisoncology.com/platform

CareersJoin Us

Open roles and how Aktis Oncology recruits, straight from the source.

aktisoncology.com/join-us

BlogAllometric Scaling of Preclinical Dosimetry for Nectin 4 Miniprotein Binders Accurately Predicts Human Absorbed Dose to Major Organs

Product updates, deep-dives, and company thinking: Aktis Oncology's 6-post archive.

  • Allometric Scaling of Preclinical Dosimetry for Nectin 4 Miniprotein Binders Accurately Predicts Human Absorbed Dose to Major Organs
  • Discovery Pre Clinical Development of Aky 1189
  • Oral Presentation at the Eortc Nci Aacr Symposium on Molecular Targets and Cancer Therapeutics 2024
  • Poster Presentation at the Asco Genitourinary Cancers Symposium Titled 225acac Aky 1189 a Nectin 4 Targeted Radiopharmaceutical in Patients with Previously Treated Locally Advanced or Metastati
  • Presentation First in Human Pet Ct Imaging with 68gaga Aky 2519 a B7 H3 Targeted Miniprotein Radioconjugate
  • Presentation at Asco Annual Meeting Titled Aky 2519 a Novel B7 H3 Targeted Radioconjugate Demonstrates Differentiated Biodistribution Profile

ContactContact Us

Sales, support, and partnership channels for reaching Aktis Oncology directly.

aktisoncology.com/contact-us

Terms

The legal agreement governing use of Aktis Oncology's products and services.

aktisoncology.com/terms